Study of Remodulin for severe pulmonary hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial is testing the safety and effectiveness of Remodulin (a treprostinil therapy) given as an injection under the skin or into a vein. It is for people with severe pulmonary arterial hypertension (PAH) who have symptoms even with daily activities or at rest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with pulmonary arterial hypertension (PAH) that is inherited or has no known cause
- Your symptoms are severe (WHO class III or IV), meaning you get short of breath with little activity or at rest
- You are already scheduled to start treatment with treprostinil (a medicine given as a shot under the skin or into a vein)
- You are able to follow the study schedule and give signed consent to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.